Consideration of within-patient diversity highlights transmission pathways and

antimicrobial resistance gene variability in vancomycin resistant *Enterococcus faecium*

Martin P McHugh,[1,2]* Kerry A Pettigrew,[1]+ Surabhi Taori,[2] Thomas J Evans,[3] Alistair

Leanord,[3,4] Stephen H Gillespie,[1] Kate E Templeton,[2] Matthew TG Holden[1]

[1] School of Medicine, University of St Andrews, St Andrews, UK

[2] Medical Microbiology, Department of Laboratory Medicine, Royal Infirmary of Edinburgh,

Edinburgh, UK

[3] School of Infection and Immunity, University of Glasgow, Glasgow, UK

[4] Scottish Microbiology Reference Laboratories, Glasgow, UK

+Current affiliation: School of Health and Life Sciences, Teesside University, Middlesbrough, UK

*Corresponding author: Martin McHugh

Email: mpm20@st-andrews.ac.uk

Telephone: (+44)131 242 6025

Short title: Investigating the diversity of VREfm within patients

Synopsis

Background: Whole genome sequencing (WGS) is increasingly applied to healthcare-

associated vancomycin-resistant *Enterococcus faecium* (VREfm) outbreaks. Within-patient

diversity could complicate transmission resolution if single colonies are sequenced from

identified cases.

Objectives: Determine the impact of within-patient diversity on transmission resolution of VREfm

Methods: Fourteen colonies were collected from VREfm positive rectal screens, single colonies

were collected from clinical samples, and Illumina WGS performed. Two isolates were selected

for Oxford Nanopore sequencing and hybrid genome assembly to generate lineage-specific

reference genomes. Mapping to closely related references was used to identify genetic

variations and closely related genomes. A transmission network was inferred for the entire

genome set using Phyloscanner.

Results: In total, 229 isolates from 11 patients were sequenced. Carriage of 2-3 sequence types

was detected in 27% of patients. Presence of antimicrobial resistance genes and plasmids was

variable within genomes from the same patient and sequence type. We identified two dominant

sequence types (ST80 and ST1424), with two putative transmission clusters of two patients

within ST80, and a single cluster of six patients within ST1424. We found transmission

resolution was impaired using fewer than 14 colonies.

Conclusions: Patients can carry multiple sequence types of VREfm, and even within related

lineages the presence of mobile genetic elements and antimicrobial resistance genes can vary.

VREfm within-patient diversity should be considered to ensure accurate resolution of

transmission networks.

INTRODUCTION

Enterococcus faecium is a leading nosocomial pathogen causing opportunistic infections mostly

in immunocompromised hosts. Antimicrobial resistance is a key concern, particularly against

front-line anti Gram-positive agents amoxicillin and vancomycin.[1] Vancomycin-resistant *E.*

faecium (VREfm) infections lead to increased length of stay, cost an estimated USD200 per

case per day, and confer mortality of 23-47%.[2–7] In 2020, vancomycin resistance of 45.6% was

reported among all *E. faecium* bloodstream isolates in Scotland, among the highest rates in

Europe.[8]

In healthcare institutions asymptomatic intestinal carriage of VREfm can lead to

shedding into the environment and transfer to other patients or staff, challenging efforts to limit

the incidence of nosocomial infections.[9] Whole genome sequencing (WGS) is increasingly

applied to investigate transmission networks and identify control measures.[10,11] Many WGS

based analyses of bacterial outbreaks, however, rely on analysing single colony picks from

clinical samples assuming that this represents the entire infecting or colonizing population within

individual patients.[12] It is increasingly recognised that within-patient diversity of bacterial

populations can be significant and can influence transmission network resolution.[13–19] Several

studies have identified that individual patients can carry multiple strains of *E. faecium*

concurrently, but few have applied this to transmission resolution.[20–24]

In this study, we aimed to identify within-patient diversity of VREfm from rectal screening

swabs and determine how this impacts transmission inference in a 1-month snapshot on a

haematology unit. We designed a sampling strategy to reliably detect within-patient diversity

and supplemented short-read and long-read sequencing to generate high-quality reference

genomes to identify genomic variants in the isolate collection.

MATERIALS AND METHODS

Isolates

Rectal swabs were collected at admission and on all inpatients on the haematology unit

developing febrile neutropenia (neutrophils <0.9x10^9/l or <1.0x10^9/l and falling after

chemotherapy, plus body temperature ≥38°C). Swabs were plated to CHROMID® VRE agar

(bioMérieux, Marcy-l'Étoile, France), species identification and vancomycin resistance were

confirmed with MALDI-TOF (Microflex instrument, Bruker, Billerica, USA) and VITEK-2

(bioMérieux) with EUCAST breakpoints. All purple colonies from VREfm positive plates were

stored at -80°C in a Microbank cryovial (Pro-Lab Diagnostics, Birkenhead, UK). Any VREfm

isolated from clinical samples within 60 days of a rectal positive were also stored. Patient

metadata was retrieved from electronic records and movements visualised with HAIviz v0.3

(https://haiviz.beatsonlab.com/). This work was approved by the NHS Scotland BioRepository

Network (Ref TR000126) and the University of St Andrews Research Ethics Committee (Ref

MD12651).

Genome Sequencing

Cryovials were re-plated on CHROMID® VRE agar, and fourteen random purple colonies were

incubated overnight in 5 ml brain heart infusion broth (Oxoid). Cells were pelleted and DNA

extracted using the DNA Mini kit on a QiaSymphony instrument (Qiagen).

Short read libraries were prepared using the Nextera XT kit (Illumina, San Diego, USA)

and sequenced with a MiSeq instrument (Illumina) using 300 bp paired-end reads on a 600-

cycle v3 reagent kit.

For long read sequencing, isolates VRED06-02 (ST1424) and VRED06-10 (ST80) were

selected at random from the first sample with multiple sequence types detected (sample

VRED06 from patient P49). Long read libraries were generated with the LSK109 Ligation

Sequencing Kit (Oxford Nanopore Technologies, Oxford, UK) and sequenced for 8h using an

R9.4 flow cell on a GridION sequencer (Oxford Nanopore Technologies) with high accuracy

basecalling in MinKNOW v19.12.6 (Oxford Nanopore Technologies).

Sequence data from this study have been deposited in the NCBI under BioProject

accession number PRJNA877253 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA877253).

Sequence Assembly and Mapping

Short reads were quality trimmed with Trimmomatic v0.32.[25] MLSTs were determined with

SRST2 v0.2.0[26] and the *E. faecium* pubMLST database.[27] A core alignment was generated by

mapping short reads to the reference genome(s) with Snippy v4.6.0 default settings

(https://github.com/tseemann/snippy) and masking all putative transposases, prophage regions,

and recombination blocks. Recombination blocks were identified with Gubbins v2.4.1.[28] Non-

ACGT bases were converted to N with snippy-clean and a core SNP alignment generated with

snp-sites v2.5.1.[29] The 130 ST80 genomes mapped to VRED06-10 generated an initial

alignment of 2,814,943 bases, 202,738 bases were masked, and the final alignment contained

96 variant sites; the 97 ST1424 genomes mapped to VRED06-02 generated an initial alignment

of 2,945,113 bases, 227,540 bases were masked, and 13 variant sites remained. Maximum-

likelihood phylogenies were constructed with IQTree v2.0.3 with automatic model selection and

1000 ultrafast bootstraps.[30–32] Phylogenies were visualised with iTOL.[33] Short read assemblies

were generated with Unicycler v0.4.8[34] and searched for antimicrobial resistance genes using

Abricate v1.0.1 (https://github.com/tseemann/abricate) with default settings and the ResFinder

database.[35]

Long reads <1000 bp were removed with Nanofilt v2.7.1[36] and adapters trimmed and

chimaeras split with Porechop v0.3.2 (https://github.com/rrwick/Porechop). Reads were split into

12 subsamples and three assemblies made with four different assemblers: Flye v2.8.1,

Redbean v2.5, Raven v1.1.10, and Miniasm v0.1.3,[37–40] giving 12 assemblies in total. A

consensus assembly was generated with Trycycler v0.3.3[41] and polished with Medaka v0.11.5

(https://github.com/nanoporetech/medaka) and 2-3 cycles of Pilon v1.23.[42] Assembly quality

was assessed with assembly-stats v1.0.1 (https://github.com/sanger-pathogens/assembly-

stats), Ideel (https://github.com/phiweger/ideel), and Busco v4.1.4.[43]

Polished assemblies were annotated with Prokka v1.14.6[44] using the Aus0004 reference

genome (Accession CP003351) with the --proteins option. Abricate identified matches to

ResFinder, VirulenceFinder, and PlasmidFinder databases[45–48] and putative prophages were

identified with PHASTER.[49] Plasmid copy numbers were estimated using short reads and

Snippy: average depth for each plasmid was divided by the average depth of the chromosome.

Plasmids in the polished assemblies were compared to each other with Mash v2.2.2.[50]

To detect plasmids, those present in the two polished assemblies were used as references

against all short read sets in Snippy and considered present if ≥85% bases were called with <20

SNPs/1000 bp.[51]

Transmission Network Inference

All short reads were mapped to the VRED06-10 ST80 reference chromosome with Snippy, the

V24 *E. faecium* ST80 genome (Accession CP036151) was included as an outgroup. An

alignment of 2,814,943 bases was generated and 1,418,409 bases masked as above. A

posterior set of phylogenies were generated with MrBayes v3.2.7.[52] Two MCMC runs of four

coupled chains were run for 5,000,000 generations, sampling every 5000. The final standard

deviation of split frequencies was 0.013, the log-likelihood was stable, and the effective sample

size of all parameters was >800. A random sample of 100 posterior trees was input to

Phyloscanner v1.6.6.[53] Sankoff parsimony reconstruction was performed with *k* parameter of

281494.5, equivalent to a within-patient diversity threshold of 10 SNPs as used in other

studies.[54] A transmission network was constructed in Cytoscape v3.9.0[55] showing edges with

complex or transmission state and >0.5 probability. The role of smaller numbers of colony picks

on transmission resolution was investigated by repeating the above with the first 3, 5, and 10

genomes per sample.

Statistical Analysis

To determine the optimal number of colonies to analyse for within-sample diversity a power

calculation was performed as described by Huebner et al:[56]

$$q \wedge n = (1 - P)$$

163   Where q = 1 – concentration of organisms, ^ = exponentiation operator, n = number of colonies

164   sequenced, and P = probability of finding one or more variants.

165   Population variants were considered distinct if they differed by >10 chromosomal

SNPs.[54] Moradigaravand *et al*[20] show rectal VREfm populations harbour minority variants at 20-

50% of the total population based on sequencing ~5 colonies. However, no minor population

variants were identified in blood cultures based on sequencing ~10 colonies.[20] For rectal

samples, we determined 14 colonies per sample would detect a variant at 20% of the population

with 95% confidence, and for blood cultures we sequenced single colonies to identify the

sequence type causing invasive disease.

172   Presence/absence matrices of antimicrobial resistance (AMR) genes were generated in

R v4.0.5 using ggplot2 and patchwork packages.[57–59]

RESULTS AND DISCUSSION

Epidemiological Context

This study was performed over one month in 2017 on an inpatient unit for haematological

malignancies, split into two wards (A and B). VREfm rectal screening was performed on all new

admissions and any inpatients with febrile episodes to inform patient placement and

antimicrobial administration. There was significant overlap between patient stays with some

patients moving between the two study wards or to other wards in the hospital (Figure 1).

Patients were cohorted or placed in single rooms when colonised with VREfm or other alert

pathogens. However, not all rooms had ensuite bathroom facilities so risk of VREfm

transmission remained. At the time of the study, surveillance systems in the hospital had not

detected any suspected VREfm outbreak within the study population.

Results of VREfm Screening

In total, 45 rectal swabs from 27 patients were screened for VREfm. Of these, 18 samples from

13 patients were VREfm positive (Table 1). Three (23.1%) colonised patients developed VREfm

bacteraemia 9, 24, or 46 days after being identified as VREfm carriers. We applied our sampling

strategy to 16 rectal screens generating 224 isolates from 11 patients, and five blood cultures

(five isolates) from two patients yielding a total of 229 isolates. Two rectal swabs and one blood

culture were not available for further study. Most patients were female, the median age was 66

years, and a range of primary diagnoses were present (Table 1). Most colonised patients had

received antibiotics in the preceding six months and 30% had received vancomycin (Table 1).

Simultaneous carriage of multiple VREfm strains

In silico MLST typing using short reads from all 229 genomes showed ST80 (n=130), ST1424

(n=97), ST789 (n=1), and ST1659 (n=1) from the hospital-associated clade A1[60] were present

(Table 2). Multiple STs were detected in three (27%) samples. Sample VRED06 from patient

P49 contained 10 (71.4%) ST80, three (21.4%) ST1424, and one (7.1%) ST789 isolate; sample

VRED07 from P14 contained 10 (71.4%) ST1424 and four (28.6%) ST80 isolates; sample

VRED11 from P50 contained 13 (92.9%) ST1424 and one (7.1%) ST1659 isolate. A further

rectal swab sample from P49 collected two days after VRED06 contained only ST1424, and a

blood culture collected nine days later also contained ST1424. P9 had three rectal swab

samples collected over 11 days and had positive blood cultures one month later, all samples

contained ST80 only. Our finding of multiple strains in 27% of patients is in line with recent

studies showing up to half of patients carry 2-4 different *E. faecium* strains, and within-patient

diversity varies over time.[20,24,61,62]

Genomic population structure of VREfm suggests recent transmission events

The chromosomes of the two strain-specific genome assemblies (Table S1) were used

as references for short-read mapping within each sequence type. Within-patient diversity was

low when genomes of the same sequence type were compared, generally differing by zero

SNPs and a maximum pairwise difference of 3 SNPs (Table 2). Similarly, insertions, deletions,

and plasmids were usually shared in genomes from the same patient. However, the presence of

DEL3 (12 bp non-coding deletion) and DEL4 (11 bp deletion in a solute binding protein) were

variable within 24 ST80 genomes from P20 with 0-2 differentiating SNPs (Figure 2). In genomes

from P9 p1_VRED06-10 and p3_VRED06-10 were variably detected despite most genomes

having no differentiating SNPs (Figure 2). Where multiple samples from the same patient were

collected over time we found low (0-3 SNPs) accumulation of SNPs and no pattern in the

prevalence of other genomic variants. Estimates of diversification rates in *E. faecium* from single

colony sampling of national isolate collections suggest 7 mutations per year,[63] other studies of

longitudinal within-patient diversification have estimated higher rates of 12.6 – 128 mutations

per year.[20,22,23] The low SNP diversity identified in our one-month collection of carriage isolates

is in keeping with these estimated mutation rates.

The ST80 genomes formed a well-structured population with five clear clusters each

separated by >10 SNPs (Figure 2). Clustered genomes differed by 0-2 SNPs and were mostly

from individual patients although two clusters included genomes from two different patients

(patients P7 and P33, and P2 and P9). All the reference plasmids were detected in the P7 and

P33 genomes and there were two insertions detected in three genomes. There was variation in

detection of p1_VRED06-10 and p3_VRED06-10 plasmids within P9 genomes, although in P2

genomes all plasmids were detected.

Mapping of the ST1424 genomes showed a much more homogeneous population than

in ST80 (Figure 3). Of the 97 ST1424 genomes, 69 had no SNPs and the remaining 28 had 1-2

SNPs differentiating them from the rest of the collection. The SNPs that were detected did not

lead to any clear clustering of genomes, except for the 14 genomes from P6 which all carried a

SNP in a penicillin-binding protein which differentiated them from the other ST1424 genomes.

Two of the P6 genomes had further independent SNPs (one each) and another genome had

lost p1_VRED06-02. No insertions were detected in the ST1424 collection, and of the six

deletions found five were only in genomes from P49. p6_VRED06-02 was not detected in 14

P24, 14 P50, and two P49 genomes, while p1_VRED06-02 was note detected in five genomes

from three patients.

Analysis of multiple VREfm colonies supports transmission resolution

A transmission network was constructed considering the phylogenetic placement of all 14

colony picks in each sample (Figure 4). The network supports transmission of ST80 between P2

and P9, and between P7 and P33, with P20 not linked to transmission. Epidemiological data

supports transmission from P33 to P7 on Ward B, as P33 screened negative early in their

admission and then screened positive six days after P7 (Figure 1, Figure 4). P9 and P2

screened positive on the same day - no shared rooms or bed spaces were identified as this was

P2's first day on Ward B so it is unclear where or when transmission may have occurred (Figure

1, Figure S1). P20 had two admissions during the study period, was negative at the end of first

admission then screened positive on re-admission suggesting they may have become colonised

outside of the hospital.

All ST1424 patients clustered together with P34 strongly linked to all patients and likely

direct transmission to P6 (Figure 4). P34 was the first ST1424 identified on Ward B, P49 was

positive six days later (having been negative earlier in admission), P14 was positive two days

after that, and P24 was positive 9 days subsequently (Figure 1). P14 and P49 had ST1424 and

ST80 in carriage samples, we did not identify sharing of the ST80 lineages in these patients

suggesting there was no direct transmission between these two patients. On Ward A, P50

screened positive with ST1424 and ST1659 on day two of admission and P6 screened positive

for ST1424 on day six. The ST1424 populations in P6 and P50 may derive from different hosts

with P6 genomes all having a single SNP and P50 genomes having multiple different SNPs and

lack the p6_VRED06-02 plasmid (Figures 3 and 4). P34 and P50 shared time on Ward A early

in the study before either were known to be VREfm positive, but there is very limited overlap in

time between P34 and P6 while both were in different wards (Figure 1). None of the patients

with ST1424 shared a room or used a bed space previously used by an identified ST1424-

positive carrier during their stay (Figure S1).

Analysing less than 14 colonies per sample produced fewer transmission links and lower

confidence (Table S2, Figure S2). Sequencing more than 14 colonies would improve the

detection of minor variants while increasing costs and turnaround time. There was low within-

patient diversity in most patients in our study so this approach may not be required in every

case. Alternatively, strain-resolved metagenomics directly on clinical samples or sweeps of

selective culture growth may be more feasible.[64–66] Further work is required to determine the

optimum sampling strategy to support infection prevention and control investigations in

healthcare settings.

Plasmids were mostly ST-specific

VRED06-02 (ST1424 reference) contained seven plasmids, and VRED06-10 (ST80 reference)

contained five plasmids. Plasmids in the two genomes were generally distinct, suggesting

limited sharing between STs within P49 (Table S3).

We sought to identify carriage of similar plasmids in the entire collection by short read

mapping (Table S4). Most plasmids were ST-specific with few examples of ST1424 genomes

carrying plasmids from the ST80 reference, and *vice versa*. However, all ST80 genomes from

P7 and P33 carried p7_VRED06-02 from ST1424, and almost all genomes appeared to carry

p4_VRED06-10. We believe the hits against the ST1424 genomes are due to cross-mapping of

reads from the related p4_VRED06-02 (Table S3). P7_VRED06-02 is unrelated to others in the

collection (Table S3), but no close links to any ST1424-positive patients were identified for P7

and P33 (Figure 4).

AMR gene load differs between closely related genomes

We next sought to determine the variability of AMR genes within the collection (Table 3 and

Figure 5). In total 13 AMR genes were detected with three (*aac(6')-Ii*, *msr(C)*, and *vanA*) present

in all genomes, two (*aph(3')-III* and *erm(B)*) in all but one genome, four (*ant(9)-Ia*, *dfrG*, *erm(A)*,

and *tet(M)*) only in ST1424 or ST1659 genomes, two genes (*ant(6)-Ia* and *tet(S)*) found only in

ST80 and ST789 genomes, and *tet(L)* found in a single ST1659 genome. The aminoglycoside

resistance gene *aac(6')-aph(2")* was variably present, found in 69.9% of all genomes.

Tetracycline resistance gene *tet(M)* was identified on the chromosome of VRED06-02 as

part of Tn*6944* (Figure S3A). *tet(M)* was identified in 62.2% of ST1424 and ST1659 genomes,

excision of Tn*6944* may be responsible for this variable presence. We identified variable within-

patient presence of *tet(M)* and no other tetracycline resistance genes (Figure 5), phenotypic

susceptibility pattern would therefore differ based on which colony was picked. However,

tetracyclines are not generally used for treatment of enterococcal human infections so the

clinical impact may be limited. Similar variable presence of the vancomycin resistance element

within patients has been described elsewhere and could lead to inappropriate use of

vancomycin when the patient harbours a resistant subpopulation.[20,21,67,68] Our study only

included vancomycin resistant isolates, so cannot resolve the potential role of variable

vancomycin resistance carriage within patients or in transmission networks. Gain and loss of

vancomycin resistance has been described in regional networks over periods of years[63].

aac(6')-aph(2'') was present on p1_VRED06-02 (ST80) and p1_VRED06-10 (ST1424).

aac(6')-aph(2'') was not detected in any ST80 genomes that were p1_VRED06-02 negative,

although only 39.8% (n=43) of genomes that carried this plasmid also carried *aac(6')-aph(2'')*. In

p1_VRED06-02, two copies of *aac(6')-aph(2'')* were surrounded by insertion sequences IS*256*,

IS*1216*, and IS*3,* providing multiple mechanisms of excision. In ST1424 *aac(6')-aph(2'')* was

detected in 97.8% (n=90) genomes with p1_VRED06-10. In p1_VRED06-10, *aac(6')-aph(2'')*

was surrounded by two copies of IS*256* similarly to Tn*6218*, although the transposition

machinery was missing (Figure S3B).[69] Another four ST1424 genomes carried *aac(6')-aph(2'')*

but not p1_VRED06-10 (Table 3 and Figure 5). Short read assemblies could not resolve the

environment of *aac(6')-aph(2'')*, but in three cases *aac(6')-aph(2'')* co-located with an IS*3* gene

suggesting mobilisation to another transposable element. The impact on phenotype is unclear –

all genomes carried *aac(6')-Ii* and *aph(3')-III* which together confer high-level resistance to the

clinically relevant aminoglycosides amikacin and gentamicin, so the loss of *aac(6')-aph(2'')* may

be more efficient for the cell without an overt change in antibiotic susceptibility. Both Tn*6994*

and Tn*6218* were first characterised in *C. difficile*, highlighting transmission of AMR elements

between nosocomial pathogens as recently described.[70]

The tetracycline resistance gene *tet(L)* was identified in a single ST1659 genome, the

gene was co-located with *tet(M)* on a 30 kb contig that was similar to Tn*6248* from *E. faecium*

over ~19 kb (Figure S3C).

We recognise some limitations. Around 60% of *E. faecium* carriers can be linked to nosocomial

transmission from other patients or reservoirs in the hospital environment.[61,71–74] Our study did

not include environmental samples, and although patients were mostly located in individual

rooms bathroom facilities were shared posing a significant environmental reservoir for VREfm.

Also, we relied on direct plating to solid VREfm screening agar for inclusion in our study.

Previous studies have shown a sensitivity of 58-96% for this approach, rising to 97-100% with a

pre-enrichment step.[75–77]

A proactive sequence-based surveillance approach should avoid large infection

outbreaks, and reduce ward closure costs and the clinical impact of invasive disease.[78–81] In our

setting, an outbreak of VREfm was suspected 3 weeks after the study collection period when P9

and P49 developed bloodstream infection concurrently but this was many weeks after VREfm

transmission had likely occurred (Figure 1 and Figure 4). Due to our study's retrospective

nature, we could not use the findings from sequencing to directly influence patient care.

To conclude, by taking account of within-patient diversity in VREfm carriage populations

we identified transmission links between patients that could supplement efforts to control

transmission within hospitals. We also show that diversity exists not just at the level of SNPs –

AMR gene presence/absence, indels, and plasmid presence all vary within and between

patients. Accounting for within-patient diversity is important for resolving VREfm transmission

using WGS-based investigations.

ACKNOWLEDGEMENTS

The authors would like to thank all staff at the Department for Medical Microbiology, Royal

Infirmary of Edinburgh for supporting this study. The authors acknowledge the

Research/Scientific Computing teams at The James Hutton Institute and NIAB for providing

computational resources and technical support for the "UK's Crop Diversity Bioinformatics HPC"

(BBSRC grant BB/S019669/1), use of which has contributed to the results reported within this

paper. Bioinformatics and Computational Biology analyses were further supported by the

University of St Andrews Bioinformatics Unit which is funded by a Wellcome Trust ISSF award

[grant 105621/Z/14/Z].

FUNDING

This work was funded by the Chief Scientist Office (Scotland) through the Scottish Healthcare

Associated Infection Prevention Institute (Reference SIRN/10).

TRANSPARENCY DELCARATIONS

The authors declare no competing interests.

REFERENCES

1. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. *Nat Rev*
Microbiol 2012; **10**: 266–78.

2. WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017.
Available at: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-
which-new-antibiotics-are-urgently-needed. Accessed April 26, 2022.

3. CDC. *Antibiotic Resistance Threats in the United States, 2019*. Atlanta, GA: U.S. Department of
Health and Human Services, CDC; 2019.

4. Ong DSY, Bonten MJM, Safdari K, *et al.* Epidemiology, management, and risk-adjusted
mortality of ICU-acquired enterococcal bacteremia. *Clin Infect Dis* 2015; **61**: 1413–20.

5. Billington EO, Phang SH, Gregson DB, *et al.* Incidence, Risk Factors, and Outcomes for
Enterococcus spp . Blood Stream Infections: A Population-Based Study. *Int J Infect Dis* 2014; **26**:
76–82.

6. Dik JWH, Dinkelacker AG, Vemer P, *et al.* Cost-analysis of seven nosocomial outbreaks in an
academic hospital. *PLoS ONE* 2016; **11**: 1–7.

7. Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG. Economic analysis of
vancomycin-resistant enterococci at a Canadian hospital: Assessing attributable cost and length
of stay. *J Hosp Infect* 2013; **85**: 54–9.

8. ARHAI Scotland. *Scottish One Health Antimicrobial Use and Antimicrobial Resistance in 2020*.
ARHAI Scotland; 2021.

9. Zhou X, Willems RJL, Friedrich AW, Rossen JWA, Bathoorn E. Enterococcus faecium: from
microbiological insights to practical recommendations for infection control and diagnostics.
Antimicrob Resist Infect Control 2020; **9**: 130.

10. Quainoo S, Coolen JPM, van Hijum SAFT, *et al.* Whole-Genome Sequencing of Bacterial
Pathogens: the Future of Nosocomial Outbreak Analysis. *Clin Microbiol Rev* 2017; **30**: 1015–63.

11. Pinholt M, Larner-Svensson H, Littauer P, *et al.* Multiple hospital outbreaks of vanA
Enterococcus faecium in Denmark, 2012-13, investigated by WGS, MLST and PFGE. *J Antimicrob
Chemother* 2015; **70**: 1–9.

12. Croucher NJ, Didelot X. The application of genomics to tracing bacterial pathogen
transmission. *Curr Opin Microbiol* 2015; **23**: 62–7.

13. Bryant JM, Grogono DM, Greaves D, *et al.* Whole-genome sequencing to identify
transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective
cohort study. *The Lancet* 2013; **381**: 1551–60.

14. Worby CJ, Lipsitch M, Hanage WP. Within-Host Bacterial Diversity Hinders Accurate
Reconstruction of Transmission Networks from Genomic Distance Data. *PLoS Comput Biol* 2014;
10: e1003549.

15. Snitkin ES, Zelazny AM, Thomas PJ, *et al.* Tracking a Hospital Outbreak of Carbapenem-
Resistant Klebsiella pneumoniae with Whole-Genome Sequencing. *Sci Transl Med* 2012; **4**:
148ra116.

16. Hall MD, Holden MT, Srisomang P, *et al.* Improved characterisation of MRSA transmission
using within-host bacterial sequence diversity. *eLife* 2019; **8**: e46402.

17. Harris SR, Cartwright EJ, Török ME, *et al.* Whole-genome sequencing for analysis of an
outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study. *Lancet Infect Dis*
2013; **13**: 130–6.

18. Okoro CK, Kingsley RA, Quail MA, *et al.* High-Resolution Single Nucleotide Polymorphism
Analysis Distinguishes Recrudescence and Reinfection in Recurrent Invasive Nontyphoidal
Salmonella Typhimurium Disease. *Clin Infect Dis* 2012; **54**: 955–63.

19. Paterson GK, Harrison EM, Murray GGR, *et al.* Capturing the cloud of diversity reveals
complexity and heterogeneity of MRSA carriage, infection and transmission. *Nat Commun* 2015;
6.

20. Moradigaravand D, Gouliouris T, Blane B, *et al.* Within-host evolution of Enterococcus
faecium during longitudinal carriage and transition to bloodstream infection in
immunocompromised patients. *Genome Med* 2017; **9**: 119.

21. Raven KE, Gouliouris T, Parkhill J, Peacock SJ. Genome-Based Analysis of Enterococcus
faecium Bacteremia Associated with Recurrent and Mixed-Strain Infection Carroll KC, ed. *J Clin*
Microbiol 2018; **56**: e01520-17.

22. Dubin KA, Mathur D, McKenney PT, *et al.* Diversification and evolution of vancomycin-
resistant Enterococcus faecium during intestinal domination. *Infect Immun* 2019; **87**: e00102-
19.

23. Bayjanov JR, Baan J, Rogers MRC, Troelstra A, Willems RJL, van Schaik W. Enterococcus
faecium genome dynamics during long-term asymptomatic patient gut colonization. *Microb*
Genomics 2019; **5**.

24. Both A, Kruse F, Mirwald N, *et al.* Population dynamics in colonizing vancomycin-resistant E.
faecium isolated from immunosuppressed patients. *J Glob Antimicrob Resist* 2022; **28**: 267–73.

25. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data.
Bioinforma Oxf Engl 2014; **30**: 2114–20.

26. Inouye M, Dashnow H, Raven L-A, *et al.* SRST2: Rapid genomic surveillance for public health
and hospital microbiology labs. *Genome Med* 2014; **6**: 1–16.

27. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb
software, the PubMLST.org website and their applications. *Wellcome Open Res* 2018; **3**.

28. Croucher NJ, Page AJ, Connor TR, *et al.* Rapid phylogenetic analysis of large samples of
recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* 2015; **43**:
e15.

29. Page AJ, Taylor B, Delaney AJ, *et al.* SNP-sites: Rapid efficient extraction of SNPs from multi-
FASTA alignments. *Microb Genomics* 2016; **2**: e000056.

30. Minh BQ, Schmidt HA, Chernomor O, *et al.* IQ-TREE 2: New Models and Efficient Methods
for Phylogenetic Inference in the Genomic Era. *Mol Biol Evol* 2020; **37**: 1530–4.

31. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the
Ultrafast Bootstrap Approximation. *Mol Biol Evol* 2018; **35**: 518–22.

32. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast
model selection for accurate phylogenetic estimates. *Nat Methods* 2017; **14**: 587–9.

33. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree
display and annotation. *Nucleic Acids Res* 2021; **49**: W293–6.

34. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies
from short and long sequencing reads. *PLoS Comput Biol* 2017; **13**: e1005595.

35. Zankari E, Hasman H, Kaas RS, *et al.* Genotyping using whole-genome sequencing is a
realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. *J*
Antimicrob Chemother 2013; **68**: 771–7.

36. De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack: visualizing and
processing long-read sequencing data. *Bioinformatics* 2018; **34**: 2666–9.

37. Kolmogorov M, Yuan J, Lin Y, Pevzner PA. Assembly of long, error-prone reads using repeat
graphs. *Nat Biotechnol* 2019; **37**: 540–6.

38. Ruan J, Li H. Fast and accurate long-read assembly with wtdbg2. *Nat Methods* 2020; **17**:
155–8.

39. Vaser R, Šikić M. Time- and memory-efficient genome assembly with Raven. *Nat Comput Sci*
2021; **1**: 332–6.

40. Li H. Minimap and miniasm: fast mapping and de novo assembly for noisy long sequences.
Bioinformatics 2016; **32**: 2103–10.

41. Wick RR, Judd LM, Cerdeira LT, *et al.* Trycycler: consensus long-read assemblies for bacterial
genomes. *Genome Biol* 2021; **22**: 266.

42. Bruce J Walker, Thomas Abeel, Terrance Shea, *et al.* Pilon: An Integrated Tool for
Comprehensive Microbial Variant Detection and Genome Assembly Improvement | PLOS ONE.
PLOS ONE 2014; **9**: e112963.

43. Simão FA, Waterhouse RM, Ioannidis P, Kriventseva EV, Zdobnov EM. BUSCO: assessing
genome assembly and annotation completeness with single-copy orthologs. *Bioinformatics*
2015; **31**: 3210–2.

44. Seemann T. Prokka: Rapid prokaryotic genome annotation. *Bioinformatics* 2014; **30**: 2068–
9.

45. Bortolaia V, Kaas Rs, Ruppe E, *et al.* ResFinder 4.0 for predictions of phenotypes from
genotypes. *J Antimicrob Chemother* 2020; **75**: 3491–500.

46. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a novel
web tool for WGS-based detection of antimicrobial resistance associated with chromosomal
point mutations in bacterial pathogens. *J Antimicrob Chemother* 2017; **72**: 2764–8.

47. Joensen Kg, Scheutz F, Lund O, *et al.* Real-time whole-genome sequencing for routine
typing, surveillance, and outbreak detection of verotoxigenic Escherichia coli. *J Clin Microbiol*
2014; **52**.

48. Carattoli A, Zankari E, Garciá-Fernández A, *et al.* In Silico detection and typing of plasmids
using plasmidfinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother*
2014; **58**: 3895–903.

49. Arndt D, Grant JR, Marcu A, *et al.* PHASTER: a better, faster version of the PHAST phage
search tool. *Nucleic Acids Res* 2016: 1–6.

50. Ondov BD, Treangen TJ, Melsted P, *et al.* Mash: fast genome and metagenome distance
estimation using MinHash. *Genome Biol* 2016; **17**: 132.

51. Pinholt M, Bayliss SC, Gumpert H, *et al.* WGS of 1058 Enterococcus faecium from
Copenhagen, Denmark, reveals rapid clonal expansion of vancomycin-resistant clone ST80
combined with widespread dissemination of a vanA-containing plasmid and acquisition of a
heterogeneous accessory genome. *J Antimicrob Chemother* 2019; **74**: 1776–85.

52. Ronquist F, Teslenko M, van der Mark P, *et al.* MrBayes 3.2: Efficient Bayesian Phylogenetic
Inference and Model Choice Across a Large Model Space. *Syst Biol* 2012; **61**: 539–42.

53. Wymant C, Hall M, Ratmann O, *et al.* PHYLOSCANNER: Inferring Transmission from Within-
and Between-Host Pathogen Genetic Diversity. *Mol Biol Evol* 2018; **35**: 719–33.

54. Higgs C, Sherry NL, Seemann T, *et al.* Optimising genomic approaches for identifying
vancomycin-resistant Enterococcus faecium transmission in healthcare settings. *Nat Commun*
2022; **13**: 509.

55. Shannon P, Markiel A, Ozier O, *et al.* Cytoscape: A Software Environment for Integrated
Models of Biomolecular Interaction Networks. *Genome Res* 2003; **13**: 2498–504.

56. Huebner RE, Dagan R, Porath N, Wasas AD, T M, Klugman KP. Lack of Utility of Serotyping
Multiple Colonies for Detection of Simultaneous Nasopharyngeal Carriage of Different
Pneumococcal Serotypes. *Pediatr Infect Dis J* 2000; **19**: 1017–20.

57. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R
Foundation for Statistical Computing; 2021. Available at: https://www.R-project.org/.

58. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York; 2016.
Available at: https://ggplot2.tidyverse.org.

59. Pedersen TL. *patchwork: The Composer of Plots*. 2020. Available at: https://CRAN.R-
project.org/package=patchwork.

60. Lebreton F, Schaik W van, McGuire AM, *et al.* Emergence of Epidemic Multidrug-Resistant
Enterococcus faecium from Animal and Commensal Strains. *mBio* 2013; **4**: e00534-13.

61. Gouliouris T, Coll F, Ludden C, *et al.* Quantifying acquisition and transmission of
Enterococcus faecium using genomic surveillance. *Nat Microbiol* 2021; **6**: 103–11.

62. Brodrick HJ, Raven KE, Harrison EM, *et al.* Whole-genome sequencing reveals transmission
of vancomycin-resistant Enterococcus faecium in a healthcare network. *Genome Med* 2016; **8**:
4.

63. Raven KE, Gouliouris T, Brodrick H, *et al.* Complex Routes of Nosocomial Vancomycin-
Resistant Enterococcus faecium Transmission Revealed by Genome Sequencing. *Clin Infect Dis*
2017; **64**: 886–93.

64. Mäklin T, Kallonen T, David S, *et al.* High-resolution sweep metagenomics using fast
probabilistic inference. *Wellcome Open Res* 2021; **5**.

65. Anyansi C, Straub TJ, Manson AL, Earl AM, Abeel T. Computational Methods for Strain-Level
Microbial Detection in Colony and Metagenome Sequencing Data. *Front Microbiol* 2020; **11**.

66. Mu A, Kwong JC, Isles NS, *et al.* Reconstruction of the Genomes of Drug-Resistant Pathogens
for Outbreak Investigation through Metagenomic Sequencing. *mSphere* 2019; **4**: e00529-18.

67. Xanthopoulou K, Wille J, Zweigner J, *et al.* Characterization of a vancomycin-resistant
Enterococcus faecium isolate and a vancomycin-susceptible E. faecium isolate from the same
blood culture. *J Antimicrob Chemother* 2020; **76**: 883–6.

68. Cárdenas AM, Andreacchio KA, Edelstein PH. Prevalence and detection of mixed-population
enterococcal bacteremia. *J Clin Microbiol* 2014; **52**: 2604–8.

69. Dingle KE, Elliott B, Robinson E, *et al.* Evolutionary History of the Clostridium difficile
Pathogenicity Locus. *Genome Biol Evol* 2014; **6**: 36–52.

70. Smith AB, Jenior ML, Keenan O, *et al.* Enterococci enhance Clostridioides difficile
pathogenesis. *Nature* 2022; **611**: 780–6.

71. Lee AS, White E, Monahan LG, Jensen SO, Chan R, van Hal SJ. Defining the Role of the
Environment in the Emergence and Persistence of vanA Vancomycin-Resistant Enterococcus
(VRE) in an Intensive Care Unit: A Molecular Epidemiological Study. *Infect Control Hosp*
Epidemiol 2018: 1–8.

72. Ford CD, Lopansri BK, Gazdik MA, *et al.* Room contamination, patient colonization pressure,
and the risk of vancomycin-resistant Enterococcus colonization on a unit dedicated to the

treatment of hematologic malignancies and hematopoietic stem cell transplantation. *Am J*
Infect Control 2016; **44**: 1110–5.

73. McDermott H, Skally M, O'Rourke J, Humphreys H, Fitzgerald-Hughes D. Near-patient
environmental contamination of an intensive care unit with Vancomycin-resistant Enterococci
(VRE) and Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae (ESBL-E) before
and after the introduction of chlorhexidine bathing for patients. *Infect Control Hosp Epidemiol*
2018: 1–2.

74. Bonten MJM, Hayden MK, Nathan C, *et al.* Epidemiology of colonisation of patients and
environment with vancomycin-resistant enterococci. *Lancet* 1996; **348**: 1615–9.

75. Gouliouris T, Blane B, Brodrick HJ, *et al.* Comparison of two chromogenic media for the
detection of vancomycin-resistant enterococcal carriage by nursing home residents. *Diagn*
Microbiol Infect Dis 2016; **85**: 409–12.

76. D'Agata EMC, Gautam S, Green WK, Tang Y-W. High rate of false-negative results of the
rectal swab culture method in detection of gastrointestinal colonization with vancomycin-
resistant enterococci. *Clin Infect Dis* 2002; **34**: 167–72.

77. Linfield RY, Campeau S, Injean P, *et al.* Practical methods for effective vancomycin-resistant
enterococci (VRE) surveillance: experience in a liver transplant surgical intensive care unit.
Infect Control Hosp Epidemiol 2018; **39**: 1178–82.

78. Gordon LG, Elliott TM, Forde B, *et al.* Budget impact analysis of routinely using whole-
genomic sequencing of six multidrug-resistant bacterial pathogens in Queensland, Australia.
BMJ Open 2021; **11**: e041968.

79. Torok E, Brodrick H, Khokhar F, *et al.* Prospective Surveillance and Rapid Whole-Genome
Sequencing Detects Two Unsuspected Outbreaks of Carbapenemase-Producing Klebsiella
pneumoniae in a UK Teaching Hospital. *Open Forum Infect Dis* 2017; **4**: S43–4.

80. Sherry NL, Gorrie CL, Kwong JC, *et al.* Multi-site implementation of whole genome
sequencing for hospital infection control: A prospective genomic epidemiological analysis.
Lancet Reg Health - West Pac 2022; **23**: 100446.

81. Forde BM, Bergh H, Cuddihy T, *et al.* Clinical Implementation of Routine Whole-genome
Sequencing for Hospital Infection Control of Multi-drug Resistant Pathogens. *Clin Infect Dis*
2023; **76**: e1277–84.

578
579
580
581

583   **Table 1** – Characteristics of patients with rectal VREfm colonisation (n = 13)

Demographics	N (%)
Female	8 (61.5)
Age, median (range) years	66 (37-77)
Primary diagnosis	
Acute myeloid leukaemia	3 (23.1)
Diffuse large B cell lymphoma	3 (23.1)
Multiple myeloma	3 (23.1)
Myelodysplasia	2 (15.4)
Chronic lymphocytic leukaemia	1 (7.7)
Mantle cell lymphoma	1 (7.7)
Antimicrobial administration	
Any antibiotics in the 7d prior to positive screen	12 (92.3)
Any antibiotics in the 6m prior to positive screen	12 (92.3)
Vancomycin in the 7d prior to positive screen	1 (7.7)
Vancomycin in the 6m prior to positive screen[a]	3 (30.0)
Outcomes within 60d of VREfm positive screen	
VREfm bloodstream infection	3 (23.1)
ICU admission	1 (7.7)
Death	0 (0)

584   [a] Information available for 10 patients

Table 2 – MLST Sequence Types Detected

Patient ID	Sample ID	Sample Type	Sample Date (days from start of study)	STs detected (n, %)	Maximum pairwise SNP distance within sample	Median (IQR) pairwise SNP distance within sample
P2	VRED01	Rectal	6	80 (14, 100)	2	0 (0 - 1)
P6	VRED16	Rectal	27	1424 (14, 100)	2	0 (0 - 1)
P7	VRED10	Rectal	18	80 (14, 100)	2	0 (0 - 1)
P9	VRED02	Rectal	6	80 (14, 100)	2	0 (0 - 0)
P9	VRED03	Rectal	8	80 (14, 100)	0	0 (0 - 0)
P9	VRED09	Rectal	17	80 (14, 100)	0	0 (0 - 0)
P9	VRED18	Blood	52	80 (1, 100)	NA	NA
P9	VRED19	Blood	52	80 (1, 100)	NA	NA
P9	VRED20	Blood	52	80 (1, 100)	NA	NA
P9	VRED21	Blood	52	80 (1, 100)	NA	NA
P14	VRED07	Rectal	17	1424 (10, 71.4) 80 (4, 26.6)	2 2	1 (0-1) 2 (1-2)
P20	VRED15	Rectal	27	80 (14, 100)	3	0 (0 - 2)
P20	VRED17	Rectal	30	80 (14, 100)	3	1 (0 - 1)
P24	VRED13	Rectal	26	1424 (14, 100)	0	0 (0 - 0)
P33	VRED12	Rectal	24	80 (14, 100)	1	0 (0 - 0)
P34	VRED04	Rectal	9	1424 (14, 100)	0	0 (0 - 0)
P34	VRED05	Rectal	14	1424 (14, 100)	1	0 (0 - 0)
P49	VRED06	Rectal	15	80 (10, 71.4) 1424 (3, 21.4) 789 (1, 7.1)	2 1 NA	0 (0 - 1) 0 (0 - 0) NA
P49	VRED08	Rectal	17	1424 (14, 100)	2	0 (0 - 1)
P49	VRED14	Blood	30	1424 (1, 100)	NA	NA
P50	VRED11	Rectal	23	1424 (13, 92.9) 1659 (1, 7.1)	3 NA	1 (0 - 2) NA

587
588

589 **Table 3** – Presence of AMR Genes

Gene	Phenotypic resistance	ST80, n = 130		ST1424, n = 97		All Genomes, n = 229	
		n (%)	Genetic element	n (%)	Genetic element	n (%)	Summary
aac(6')-aph(2'')	Amikacin, Gentamicin, Kanamycin, Streptomycin, Tobramycin	65 (50.0)	p1_VRED06-10	94 (96.9)	p1_VRED06-02	160 (69.9)	Variable in ST80/ST1424/ST789
aac(6')-Ii	Gentamicin, Tobramycin	130 (100)	Chromosome	97 (100)	Chromosome	229 (100)	All genomes
ant(6)-Ia	Streptomycin	130 (100)	p3_VRED06-10	0 (0)	NA	131 (57.2)	All ST80/ST789
ant(9)-Ia	Spectinomycin	0 (0)	NA	97 (100)	Chromosome	97 (42.4)	All ST1424
aph(3')-III	Amikacin, Kanamycin, Neomycin	130 (100)	p3_VRED06-10	97 (100)	p2_VRED06-02	228 (99.6)	All ST80/ST789/ST1424
dfrG	Trimethoprim	0 (0)	NA	97 (100)	Chromosome	97 (42.4)	All ST1424
erm(A)	Clindamycin, Erythromycin, Quinupristin	0 (0)	NA	97 (100)	Chromosome	97 (42.4)	All ST1424
erm(B)	Clindamycin, Erythromycin, Quinupristin	129 (99.2)	p1_VRED06-10, p3_VRED06-10	97 (100)	p2_VRED06-02	228 (99.6)	All except one ST80 genome
msr(C)	Erythromycin, Quinupristin	130 (100)	Chromosome	97 (100)	Chromosome	229 (100)	All genomes
tet(L)	Doxycycline, Tetracycline	0 (0)	NA	0 (0)	NA	1 (0.4)	Only ST1659
tet(M)	Doxycycline, Minocycline, Tetracycline	0 (0)	NA	60 (61.9)	Chromosome	61 (26.6)	Variable in ST1424/ST1659
tet(S)	Doxycycline, Minocycline, Tetracycline	130 (100)	p3_VRED06-10	0 (0)	NA	131 (57.2)	All ST80/ST789
VanA	Teicoplanin, Vancomycin	97 (100)	p2_VRED06-02	97 (100)	p2_VRED06-02	229 (100)	All genomes

590
591

594   **Figure 1** – Patient timeline. Each row denotes the location of a patient during admission, blocks

595   denote hospital stay, circles denote VREfm cultures, stars denote bloodstream isolates, dotted

596   lines indicate the start and end of prospective collection of screening isolates for this study. This

597   study was undertaken mainly within Wards A and B, although patients were moved to different

598   wards within the hospital during their stay and were often admitted through the assessment unit.

Figure 2 – Phylogeny of ST80 isolates showing structured population with three patient specific

clusters and two clusters indicating putative patient-patient transmission of VREfm. All ST80

isolates (n=130) mapped to VRED06-10 chromosome and phylogeny built on SNP sites (n=96)

after removal of putative transposable and recombinant regions. Tree unrooted.

Figure 3 – Unrooted phylogeny of ST1424 genomes showing homogeneous population

suggestive of recent transmission outbreak. ST1424 genomes (n=97) mapped to VRED06-02

chromosome and phylogeny built on SNP sites (n=13) after removal of putative transposable

and recombinant regions. Tree unrooted.

Figure 4 – Phyloscanner transmission network. Each patient is represented by a node coloured

by detection of the two outbreak STs. Edge thickness corresponds to fraction of Phyloscanner

trees with given relationship, relationship fraction is printed alongside each edge, and edge

colour based on type of relationship (orange, direct transmission; blue, transmission but

direction unclear).

Figure 5 – Detection of antimicrobial resistance genes. Panels represent different patients;

resistance genes are plotted on the y-axis and isolates on the x-axis. Presence of a gene is

represented by a filled square and coloured based on the MLST of the genome.

624